Novocure reports preliminary 2023 revenue $509M (-5% YoY); NSCLC PMA submitted to FDA

NovoCure Ltd

2023-FY EPS reported -$1.95 revenue$509,338,000

Preliminary FY 2023 net revenues $509.3M, down 5% YoY on reduced US claim collections.
Q4 2023 net revenues $133.8M, up 4% YoY; US contributed $91.3M, Germany $14.7M.
1,564 prescriptions in Q4 (+14% YoY); 3,755 active patients (+9% vs Q4 2022).
PMA application for TTFields in NSCLC submitted to FDA/PMDA in December 2023.
Appointed Dr. Nicolas Leupin as Chief Medical Officer effective Jan 1, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NovoCure Ltd reported the quarter and year ended December 31, 2023 results: revenue $509.3 million.

Period: the quarter and year ended December 31, 2023
Revenue: $509.3 million
Result: preliminary results

Exact text from the filing

--- EX-99.1 (EX-99.1) --- Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update Preliminary full year 2023 net revenues of $509 million and fourth quarter net revenues of $134 million PMA application for TTFields in NSCLC submitted for review to U.S. Food and Drug Administration Nicholas Leupin M.D. appointed as

View on SEC.gov

Browse all earnings releases →

NovoCure Ltd filing history →

Source: SEC EDGAR

accession 0001645113-24-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.